Paper19879639
Current state of biomarker development for clinical application in epithelial ovarian cancer.
Moore RG and 2 others. Gynecol Oncol, 2010. Cited by 73 papers, by iCite.
Cite this record
ConductScience Library. Current state of biomarker development for clinical application in epithelial ovarian cancer. Papers, record 19879639. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19879639
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomarkers, Tumor | Major topic |
| Ovarian Neoplasms | Major topic |
| CA-125 Antigen | |
| Female | |
| Humans | |
| Mass Screening | |
| Risk Assessment |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA016672 | NCI NIH HHS | United States | P30CA016672 | PubMed and NIH | NIH RePORTER |
| P50 CA083639 | NCI NIH HHS | United States | P50CA083639 | PubMed and NIH | NIH RePORTER |
| R01 CA136491 | NCI NIH HHS | United States | R01CA136491 | PubMed and NIH | NIH RePORTER |
| P50 CA83639 | NCI NIH HHS | United States | P50CA083639 | PubMed and NIH | NIH RePORTER |
References63
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19423517 | Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. | Cancer Epidemiol Biomarkers Prev | 2009 | https://conductscience.org/library/papers/19423517 | PubMed |
| 2 | 8166218 | The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. | Am J Obstet Gynecol | 1994 | https://conductscience.org/library/papers/8166218 | PubMed |
| 3 | 19337252 | Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. | Br J Cancer | 2009 | https://conductscience.org/library/papers/19337252 | PubMed |
| 4 | 17420977 | Predictors of comprehensive surgical treatment in patients with ovarian cancer. | Cancer | 2007 | https://conductscience.org/library/papers/17420977 | PubMed |
| 5 | 8805927 | Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. | Ann Oncol | 1996 | https://conductscience.org/library/papers/8805927 | PubMed |
| 6 | 17954908 | Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. | Proc Natl Acad Sci U S A | 2007 | https://conductscience.org/library/papers/17954908 | PubMed |
| 7 | 8634992 | Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. | Cancer | 1995 | https://conductscience.org/library/papers/8634992 | PubMed |
| 8 | 17473066 | Total inhibin is a potential serum marker for epithelial ovarian cancer. | J Clin Endocrinol Metab | 2007 | https://conductscience.org/library/papers/17473066 | PubMed |
| 9 | 16394300 | Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16394300 | PubMed |
| 10 | 12743136 | Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/12743136 | PubMed |
| 11 | 19282241 | Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). | Lancet Oncol | 2009 | https://conductscience.org/library/papers/19282241 | PubMed |
| 12 | 8760716 | Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. | Br J Obstet Gynaecol | 1996 | https://conductscience.org/library/papers/8760716 | PubMed |
| 13 | 11198956 | Epithelial ovarian cancer: prevention, diagnosis, and treatment. | CA Cancer J Clin | 1999 | https://conductscience.org/library/papers/11198956 | PubMed |
| 14 | 12468197 | ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. | Obstet Gynecol | 2002 | https://conductscience.org/library/papers/12468197 | PubMed |
| 15 | 15781627 | Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. | Cancer Res | 2005 | https://conductscience.org/library/papers/15781627 | PubMed |
| 16 | 18604735 | Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish 'MALOVA'ovarian cancer study. | Pathology | 2008 | https://conductscience.org/library/papers/18604735 | PubMed |
| 17 | 7028788 | Reactivity of a monoclonal antibody with human ovarian carcinoma. | J Clin Invest | 1981 | https://conductscience.org/library/papers/7028788 | PubMed |
| 18 | 2227570 | Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease. | Gynecol Oncol | 1990 | https://conductscience.org/library/papers/2227570 | PubMed |
| 19 | 2418395 | Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. | Obstet Gynecol | 1986 | https://conductscience.org/library/papers/2418395 | PubMed |
| 20 | 19240799 | Development and preliminary evaluation of a multivariate index assay for ovarian cancer. | PLoS One | 2009 | https://conductscience.org/library/papers/19240799 | PubMed |
Cited by33
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 73 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42597227 | Integration of serological markers with O-RADS ultrasound risk stratification achieves high diagnostic accuracy for early ovarian cancer: development and validation of an interpretable model. | Am J Cancer Res | 2026 | https://conductscience.org/library/papers/42597227 | PubMed |
| 41515549 | Diagnostic Value of CA-125 and Other Tumor Biomarkers in Children with Suspected Malignancy: A Retrospective Cohort Study. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/41515549 | PubMed |
| 40598419 | Peritoneal cavity-derived small extracellular vesicles from aged tumor-naïve hosts promote ovarian cancer adhesion and invasion. | Cell Commun Signal | 2025 | https://conductscience.org/library/papers/40598419 | PubMed |
| 37884576 | Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer. | Sci Rep | 2023 | https://conductscience.org/library/papers/37884576 | PubMed |
| 36719438 | A label-free dual immunosensor for the simultaneous electrochemical determination of CA125 and HE4 biomarkers for the early diagnosis of ovarian cancer. | Anal Bioanal Chem | 2023 | https://conductscience.org/library/papers/36719438 | PubMed |
| 36713666 | Copenhagen index (CPH-I) is more favorable than CA125, HE4, and risk of ovarian malignancy algorithm (ROMA): Nomogram prediction models with clinical-ultrasonographic feature for diagnosing ovarian neoplasms. | Front Surg | 2022 | https://conductscience.org/library/papers/36713666 | PubMed |
| 36082820 | Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome. | Int J Oncol | 2022 | https://conductscience.org/library/papers/36082820 | PubMed |
| 32393810 | miR-6086 inhibits ovarian cancer angiogenesis by downregulating the OC2/VEGFA/EGFL6 axis. | Cell Death Dis | 2020 | https://conductscience.org/library/papers/32393810 | PubMed |
| 31608277 | Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives. | Front Cell Dev Biol | 2019 | https://conductscience.org/library/papers/31608277 | PubMed |
| 31122127 | Long noncoding RNA MAGI1-IT1 promoted invasion and metastasis of epithelial ovarian cancer via the miR-200a/ZEB axis. | Cell Cycle | 2019 | https://conductscience.org/library/papers/31122127 | PubMed |
| 30516730 | Can Presurgical Ultrasound Predict Survival in Women With Ovarian Masses? | Ultrasound Q | 2019 | https://conductscience.org/library/papers/30516730 | PubMed |
| 30024542 | A preliminary study: The sequential use of the risk malignancy index and contrast-enhanced ultrasonography in differential diagnosis of adnexal masses. | Medicine (Baltimore) | 2018 | https://conductscience.org/library/papers/30024542 | PubMed |
| 28927094 | Genomic markers of ovarian adenocarcinoma and its relevancy to the effectiveness of chemotherapy. | Oncol Lett | 2017 | https://conductscience.org/library/papers/28927094 | PubMed |
| 28452952 | Ultrasound Monitoring of Extant Adnexal Masses in the Era of Type 1 and Type 2 Ovarian Cancers: Lessons Learned From Ovarian Cancer Screening Trials. | Diagnostics (Basel) | 2017 | https://conductscience.org/library/papers/28452952 | PubMed |
| 28202518 | Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. | Cancer Res | 2017 | https://conductscience.org/library/papers/28202518 | PubMed |
| 28008951 | The C-terminus of IGFBP-5 suppresses tumor growth by inhibiting angiogenesis. | Sci Rep | 2016 | https://conductscience.org/library/papers/28008951 | PubMed |
| 27997533 | Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. | PLoS Med | 2016 | https://conductscience.org/library/papers/27997533 | PubMed |
| 27802199 | Placental type alkaline phosphatase tissue expression in ovarian serous carcinoma. | Cancer Biomark | 2016 | https://conductscience.org/library/papers/27802199 | PubMed |
| 26005273 | Comparison of specific ovarian tumor markers by elecsys analyzer 2010. | Acta Inform Med | 2015 | https://conductscience.org/library/papers/26005273 | PubMed |
| 25225597 | In 2014, can we do better than CA125 in the early detection of ovarian cancer? | World J Biol Chem | 2014 | https://conductscience.org/library/papers/25225597 | PubMed |
Genes15
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19879639
GET https://conductscience.org/api/papers/v1/19879639/references?page=2